Aug. 17 at 2:44 AM
$MDXH this ExoDX acquisition is a game changer.
$20MM of rev next year, growing 30%+. Bio-techne paid
$250MM for it in 2018, before it even had insurance coverage.
$MDXH got it for
$15MM over 4 years.
The one analyst who has updated numbers since the deal has
$150MM+ of revenue in 2026 for
$MDXH.
3x =
$450MM -
$100MM net debt (fully loaded for future earnings-outs) =
$350MM / 52mm shares ~
$7/sh vs
$2.80 now.
I think we get there in 12 months, with a big jump coming in November when they announce q3 and provide more specific guidance on the ExoDX deal.
